HLA-C and neoplasm: The main effectors of CIK cells are the NK-like T lymphocytes (CD3+ CD56+) that have potentially enhanced and broad antitumor activity and do not depend on TCR and MHC activity but still can elicit both MHC-restricted and MHC-unrestricted anti-tumor cytotoxicity (7, 37).